Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07315126

Reliability of Transcutaneous Bilirubin Measurement According to the Skin Colour of Newborns

Neonatal jaundice is a physiological process characterized by a yellow coloration of the skin and mucous membranes linked to an increase in a pigment: bilirubin. However, an excessive accumulation of bilirubin can lead to neurological complications: kernicterus. The screening for pathological jaundice is carried out through daily measurements of transcutaneous bilirubin using non-invasive devices (bilirubinometers). The diagnosis is made by measuring blood bilirubin levels and comparing them with reference curves. In newborns with dark skin, transcutaneous bilirubin measurements may be inaccurate because melanin interferes with the bilirubinometers.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Neonatal jaundice is a physiological process characterized by a yellow coloration of the skin and mucous membranes. It is caused by an accumulation of bilirubin in the blood. Bilirubin is a product of haemolysis, the breakdown of haem. It circulates in the blood bound to albumin. The unconjugated fraction that is not bound to albumin is neurotoxic. This physiological process must be monitored because free bilirubin is neurotoxic. Due to the immaturity of the blood-brain barrier, it can cross into the brain and damage the basal ganglia. In this case, the condition is referred to as kernicterus, which can cause acute and then chronic encephalopathies, leading to neurosensory disorders and disability in children.

Prevention of kernicterus relies on the detection of excessively high bilirubin concentrations. However, diagnosis requires an invasive blood sample to measure serum bilirubin level. Clinical screening based on the color of the newborn's skin and eyes is insufficient and must be complemented by non-invasive photometric screening using a transcutaneous bilirubinometer (a light flash on the skin). The device estimates the level of bilirubin in the blood. Measurements are performed daily by midwives during the mother and newborn's stay in the maternity ward within the first 3 to 5 days after birth. Unfortunately, the reliability of this screening appears to be lower in newborns with darker skin tones.

Between 2011 and 2012, the National Reference Center for Perinatal Hemobiology (CNRHP) recorded five cases of kernicterus in France, two of which involved delayed screening due to the newborns' dark skin. In both cases, an exchange transfusion (the last-resort treatment) had to be performed. In 2019, N'Guessan et al. reported a similar case in which, despite the presence of jaundice risk factors and a transcutaneous bilirubin level above the alert threshold, the medical team was reassured and concluded that the high reading was a discrepancy related to the infant's dark skin, without performing a confirmatory blood test.

Although most studies show a good correlation between transcutaneous bilirubin (TcB) and serum bilirubin (TSB) levels, they all report an overestimation of TcB values in newborns with darker skin. This does not generally compromise the detection of severe jaundice but may lead to a greater number of invasive blood samples to verify the results.

The methodology of most of these studies is questionable, as they refer to older-generation photometric devices, or use unvalidated colorimetric scales, and sometimes even subjective clinical assessments to determine skin color.

In 2017, a study including 6,373 preterm African-American newborns proposed a specific transcutaneous bilirubin nomogram for dark-skinned infants, with adjusted thresholds for BiliCheck© and JM-103© devices. However, these specific curves have never been externally validated and are therefore not used in routine clinical practice.

The question of the reliability of transcutaneous bilirubin measurements for jaundice screening according to skin color thus remains highly relevant.

To increase knowledge on the subject, it seems necessary to us to carry out a rigorous study of the reliability of transcutaneous bilirubin measurements performed routinely with a new-generation bilirubinometer for the screening of jaundice according to skin color. The children will be classified into three skin color groups using the Fitzpatrick classification: light skin, intermediate skin, and dark skin.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Born from 36 weeks of amenorrhea
  • Hospitalized in the postnatal ward or kangaroo care unit
  • Requiring a blood test for bilirubin analysed at the Cochin laboratory.
  • No objection from both holders of parental authority.

Exclusion criteria

  • Having received phototherapy treatment within the last 24 hours

Treatment and study plan

Skin color assessment

Procedure

Each participant's skin color is evaluated according to the Fitzpatrick skin type classification. All other care is standard, and no additional treatment is administered.

Primary outcomes

  1. To evaluate the reliability of transcutaneous bilirubin measurements performed routinely with a new-generation bilirubinometer to screen for jaundice according to the degree of skin pigmentation of newborns, determined using a published scale, the Fitzpa

    Time frame: First two days of life

    Based on the first transcutaneous and serum bilirubin assessments

Secondary outcomes

  1. To evaluate whether the reliability of transcutaneous bilirubin measurements differs between newborns with dark or intermediate skin phototypes and those with light skin phototyp

    Time frame: 1 to 7 days

    Correlation coefficients between transcutaneous bilirubin and serum bilirubin in the three skin pigmentation groups (light, intermediate, dark)

  2. To compare transcutaneous and serum bilirubin values within each skin pigmentation group and across the overall population

    Time frame: First two days of life

    First measurement of transcutaneous and serum bilirubin performed during newborn follow-up

  3. To estimate the probability that a positive screening result truly corresponds to jaundice in the newborn, according to the degree of skin pigmentation and in the overall population

    Time frame: 1 to 7 days

    Positive predictive value (PPV) of the current screening method-based on a common nomogram for all newborns and jaundice risk factors-according to skin pigmentation level and in the overall population

  4. To determine, according to the degree of skin pigmentation and in the overall population, the number of invasive blood samples performed due to an overestimation of transcutaneous bilirubin when serum bilirubin levels were within physiological ranges

    Time frame: 1 to 7 days

    Rate of invasive blood samples performed in newborns with physiological serum bilirubin levels, according to skin pigmentation level and in the overall population

  5. To determine, in newborns with intermediate or dark phototypes, based on the specific nomograms published in 2017 and integrated into the screening algorithm, the number of invasive blood samples avoided, and to specify whether these cases actually corre

    Time frame: 1 to 7 days

    Rate of invasive samples avoided in newborns with intermediate/dark phototypes thanks to the use of the specific curves published in 2017 (bilirubinometer JM-103) integrated into the screening algorithm, distinguishing cases with or without jaundice

  6. To describe the evolution of the newborns' phototype during the first days of life and assess its potential impact on the reliability of transcutaneous bilirubin measurements

    Time frame: 1 to 7 days

    Fitzpatrick scale and measurements of transcutaneous and serum bilirubin during newborn follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Aline DECHANET

CONTACT

[email protected]

Harmony PLACERDAT

CONTACT

[email protected]

07 61 67 30 15 ext. +33

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Acronym: BILICOLOR

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 2, 2026
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.